Identification of a subset of patients with acute myeloid leukemia characterized by long-term in vitro proliferation and altered cell cycle regulation of the leukemic cells

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 11, 2014, Pages 1237-1251

  Hatfield, Kimberley Joanne ^a   Reikvam, Håkon ^b   Bruserud, Øystein ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Acute myeloid leukemia; Cell cycle; Colony forming unit assay; Cytokines; Endothelial cells; Progenitor cells

Indexed keywords

BUB1 RELATED PROTEIN; CXCL11 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FLT3 LIGAND; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; RECOMBINANT GROWTH FACTOR; SCATTER FACTOR; STEM CELL FACTOR; THROMBOPOIETIN; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; SIGNAL PEPTIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CELL COUNT; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL VIABILITY; CFU COUNTING; CLINICAL ARTICLE; CLONOGENESIS; COLONY FORMING CELL; CONTROLLED STUDY; CYTOKINE RELEASE; DNA REPLICATION; ENDOTHELIUM CELL; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; IN VITRO STUDY; LEUKEMIA CELL; LONG TERM CARE; MICROARRAY ANALYSIS; MITOSIS; PATIENT IDENTIFICATION; UMBILICAL VEIN ENDOTHELIAL CELL; ACUTE MYELOBLASTIC LEUKEMIA; CANCER STEM CELL; CELL CULTURE; CELL CYCLE; COCULTURE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; TIME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; ENDOTHELIAL CELLS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOID, ACUTE; MICROARRAY ANALYSIS; MIDDLE AGED; NEOPLASTIC STEM CELLS; TIME FACTORS; YOUNG ADULT;

EID: 84911462026     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.957671     Document Type: Article

References (76)

1. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-74
2. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-51
3. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013;368:2059-74
4. Irish JM, Hovland R, Krutzik PO, et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004;118:217-28
5. Grimwade D, Hills RK. Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program 2009;2009:385-95
6. Bruserud O, Gjertsen BT, Foss B, et al. New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of aml cells - the present use in experimental studies and the possible importance for future therapeutic approaches. Stem Cells 2001;19:1-11
7. Horton SJ, Huntly BJ. Recent advances in acute myeloid leukemia stem cell biology. Haematologica 2012;97:966-74
8. Mayani H, Flores-Figueroa E, Chavez-Gonzalez A. In vitro biology of human myeloid leukemia. Leuk Res 2009;33:624-37
9. van Gosliga D, Schepers H, Rizo A, et al. Establishing long-term cultures with self-renewing acute myeloid leukemia stem/progenitor cells. Exp Hematol 2007;35:1538-49
10. Ailles LE, Gerhard B, Hogge DE. Detection and characterization of primitive malignant and normal progenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytokines. Blood 1997;90:2555-64
11. Bruserud O, Hovland R, Wergeland L, et al. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica 2003;88:416-28
12. Hatfield KJ, Hovland R, Oyan AM, et al. Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia 2008;22:287-93
13. Mosevoll KA, Akkok CA, Hervig T, et al. Stem cell mobilization and harvesting by leukapheresis alters systemic cytokine levels in patients with multiple myeloma. Cytotherapy 2013;15:850-60
14. Reikvam H, Tamburini J, Skrede S, et al. Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect. Br J Haematol 2014;164:200-11
15. Stavrum AK, Petersen K, Jonassen I, et al. Analysis of gene-expression data using J-Express. Curr Protoc Bioinformatics 2008;Chapter 7:Unit 7 3
16. Ryningen A, Stapnes C, Bruserud O. Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting. Leuk Res 2007;31:1303-13
17. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7
18. van Rhenen A, Feller N, Kelder A, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005;11:6520-7
19. Blair A, Hogge DE, Sutherland HJ. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR. Blood 1998;92:4325-35
20. Murohashi I, Tohda S, Suzuki T, et al. Autocrine growth mechanisms of the progenitors of blast cells in acute myeloblastic leukemia. Blood 1989;74:35-41
21. Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000;95:2637-44
22. Shih TT, Hou HA, Liu CY, et al. Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival. Blood 2009;113:3161-7
23. Maxwell CA, Keats JJ, Crainie M, et al. RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability. Mol Biol Cell 2003;14:2262-76
24. Meraldi P, Sorger PK. A dual role for Bub1 in the spindle checkpoint and chromosome congression. EMBO J 2005;24:1621-33
25. Raemaekers T, Ribbeck K, Beaudouin J, et al. NuSAP, a novel microtubule-associated protein involved in mitotic spindle organization. J Cell Biol 2003;162:1017-29
26. Ribbeck K, Groen AC, Santarella R, et al. NuSAP, a mitotic RanGTP target that stabilizes and cross-links microtubules. Mol Biol Cell 2006;17:2646-60
27. Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 2010;10:825-41
28. D'Angiolella V, Esencay M, Pagano M. A cyclin without cyclin-dependent kinases: cyclin F controls genome stability through ubiquitin-mediated proteolysis. Trends Cell Biol 2013;23:135-40
29. Koffa MD, Casanova CM, Santarella R, et al. HURP is part of a Ran-dependent complex involved in spindle formation. Current Biol 2006;16:743-54
30. Khadka DB, Cho WJ. Topoisomerase inhibitors as anticancer agents: a patent update. Expert opin Ther pat 2013;23:1033-56
31. Majka J, Burgers PM. The PCNA-RFC families of DNA clamps and clamp loaders. Prog Nucleic Acid Res Mol Biol 2004;78:227-60
32. Petit MM, Schoenmakers EF, Huysmans C, et al. LHFP, a novel translocation partner gene of HMGIC in a lipoma, is a member of a new family of LHFP-like genes. Genomics 1999;57:438-41
33. Hartsink-Segers SA, Zwaan CM, Exalto C, et al. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target. Leukemia 2013;27:560-8
34. Ikezoe T, Yang J, Nishioka C, et al. A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Mol Cancer Ther 2007;6:1851-7
35. Lin SF, Lin PM, Yang MC, et al. Expression of hBUB1 in acute myeloid leukemia. Leuk Lymphoma 2002;43:385-91
36. Snauwaert S, Vanhee S, Goetgeluk G, et al. RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia. Haematologica 2012;97:1539-47
37. Tsykunova G, Reikvam H, Ahmed AB, et al. Targeting of polo-like kinases and their cross talk with Aurora kinases - possible therapeutic strategies in human acute myeloid leukemia? Expert Opin Investig Drugs 2012;21:587-603
38. Tzankov A, Strasser U, Dirnhofer S, et al. In situ RHAMM protein expression in acute myeloid leukemia blasts suggests poor overall survival. Ann Hematol 2011;90:901-9
39. Wadia PP, Coram M, Armstrong RJ, et al. Antibodies specifically target AML antigen NuSAP1 after allogeneic bone marrow transplantation. Blood 2010;115:2077-87
40. Chen CC, Gau JP, You JY, et al. Prognostic significance of beta-catenin and topoisomerase IIalpha in de novo acute myeloid leukemia. Am J Hematol 2009;84:87-92
41. Wang YH, Takanashi M, Tsuji K, et al. Level of DNA topoisomerase IIalpha mRNA predicts the treatment response of relapsed acute leukemic patients. Leuk Res 2009;33:902-7
42. Lockwood WW, Thu KL, Lin L, et al. Integrative genomics identified RFC3 as an amplified candidate oncogene in esophageal adenocarcinoma. Clin Cancer Res 2012;18:1936-46
43. Ricke RM, van Deursen JM. Aurora B hyperactivation by Bub1 overexpression promotes chromosome missegregation. Cell cycle 2011;10:3645-51
44. Liao W, Liu W, Yuan Q, et al. Silencing of DLGAP5 by siRNA significantly inhibits the proliferation and invasion of hepatocellular carcinoma cells. PLoS ONE 2013;8:e80789
45. Gudmundsson KO, Thorsteinsson L, Sigurjonsson OE, et al. Gene expression analysis of hematopoietic progenitor cells identifies Dlg7 as a potential stem cell gene. Stem Cells 2007;25:1498-506
46. Cohen Y, Gutwein O, Garach-Jehoshua O, et al. The proliferation arrest of primary tumor cells out-of-niche is associated with widespread downregulation of mitotic and transcriptional genes. Hematology 2014;19(5):286-92
47. Lee YP, Wong CH, Chan KS, et al. In vivo FRET imaging revealed a regulatory role of RanGTP in kinetochore-microtubule attachments via Aurora B kinase. PLoS One 2012;7:e45836
48. Arnaoutov A, Dasso M. The Ran GTPase regulates kinetochore function. Dev Cell 2003;5:99-111
49. Doan PL, Chute JP. The vascular niche: home for normal and malignant hematopoietic stem cells. Leukemia 2012;26:54-62
50. Foss B, Nesthus I, Bergheim J, et al. Serum levels of thrombopoietin and stem cell factor in acute leukemia patients with chemotherapy-induced cytopenia and complicating infections. Platelets 1999;10:17-23
51. Lyman SD, Jacobsen SE. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998;91:1101-34
52. Gibson FM, Scopes J, Daly S, et al. IL-3 is produced by normal stroma in long-term bone marrow cultures. Br J Haematol 1995;90:518-25
53. Taussig DC, Vargaftig J, Miraki-Moud F, et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood 2010;115:1976-84
54. Hatfield K, Ryningen A, Corbascio M, et al. Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts. Int J Cancer 2006;119:2313-21
55. Ninomiya M, Abe A, Katsumi A, et al. Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice. Leukemia 2007;21:136-42
56. Schuurhuis GJ, Meel MH, Wouters F, et al. Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells. PLoS One 2013;8:e78897
57. Motorin D, Bakken A, Foss Abrahamsen J, et al. Characterization of clonogenic progenitors in autologous peripheral blood stem cell grafts: evaluation of a simple in vitro assay suitable for routine clinical use. Hematology (Am Soc Hematol Educ Program) 2003;8:313-18
58. Ohler L, Geissler K. Semi-solid colony growth in acute myeloid leukemia and its relation to cytogenetic risk groups. Leuk Lymphoma 2002;43:1743-7
59. Schnerch D, Yalcintepe J, Schmidts A, et al. Cell cycle control in acute myeloid leukemia. Am J Cancer Res 2012;2:508-28
60. Uemura N, Nakanishi Y, Kato H, et al. Antibody-based proteomics for esophageal cancer: identification of proteins in the nuclear factor-kappaB pathway and mitotic checkpoint. Cancer Sci 2009;100:1612-22
61. Kuo TC, Lu HP, Chao CC. The tyrosine kinase inhibitor sorafenib sensitizes hepatocellular carcinoma cells to taxol by suppressing the HURP protein. Biochem Pharmacol 2011;82:184-94
62. Yang J, Splittgerber R, Yull FE, et al. Conditional ablation of Ikkb inhibits melanoma tumor development in mice. J Clin Invest 2010;120:2563-74
63. Guzman ML, Li X, Corbett CA, et al. Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood 2007;110:4436-44
64. Koch HB, Zhang R, Verdoodt B, et al. Large-scale identification of c-MYC-associated proteins using a combined TAP/MudPIT approach. Cell cycle 2007;6:205-17
65. Bruserud O, Ryningen A, Olsnes AM, et al. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica 2007;92:332-41
66. Kentsis A, Reed C, Rice KL, et al. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med 2012;18:1118-22
67. Bruserud O, Aasen I, Akselsen PE, et al. Interleukin 1 receptor antagonist (IL1RA) in acute leukaemia: IL1RA is both secreted spontaneously by myelogenous leukaemia blasts and is a part of the acute phase reaction in patients with chemotherapy-induced leucopenia. Eur J Haematol 1996;57:87-95
68. Estrov Z, Kurzrock R, Estey E, et al. Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. Blood 1992;79:1938-45
69. Stosic-Grujicic S, Basara N, Milenkovic P, et al. Modulation of acute myeloblastic leukemia (AML) cell proliferation and blast colony formation by antisense oligomer for IL-1 beta converting enzyme (ICE) and IL-1 receptor antagonist (IL-1ra). J Chemother 1995;7:67-70
70. Ortiz LA, Dutreil M, Fattman C, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA 2007;104:11002-7
71. Weimar IS, Miranda N, Muller EJ, et al. Hepatocyte growth factor/scatter factor (HGF/SF) is produced by human bone marrow stromal cells and promotes proliferation, adhesion and survival of human hematopoietic progenitor cells (CD34+). Exp Hematol 1998;26:885-94
72. Kastrinaki MC, Pavlaki K, Batsali AK, et al. Mesenchymal stem cells in immune-mediated bone marrow failure syndromes. Clin Develop Immunol 2013;2013:265608
73. Lowenberg B, van Putten WL, Touw IP, et al. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. N Engl J Med 1993;328:614-19
74. Barreyro L, Will B, Bartholdy B, et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood 2012;120:1290-8
75. Kim JG, Sohn SK, Kim DH, et al. Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. Leuk Lymphoma 2005;46:885-91
76. Verstovsek S, Kantarjian H, Estey E, et al. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia 2001;15:1165-70